.svg)
Retatrutide: 28.7% Weight Loss. Nearly Double Ozempic, Surpassing Zepbound
Discover the next generation of weight loss treatment - more effective, longer-lasting, and designed for real results.
Better Overall Health
Less Cravings, Less Struggle
Boost Your Sex Life
Sustainable Weight Loss
%201.webp)
.webp)
How Retatrutide Works: Triple Hormone Mechanism
Innovation that transforms your weight and health
Reduces Appetite Naturally
Retatrutide signals your brain to feel full faster, helping you eat less comfortably each day.
Boosts Metabolic Health
Retatrutide supports better blood sugar control and enhances metabolism for steady weight loss.
Supports Lasting Results
By combining appetite and metabolic benefits, Retatrutide helps maintain long-term weight loss.
.webp)
A Quarter of Body Weight Lost in Under a Year
"It is remarkable that participants with obesity who received Retatrutide lost a quarter of their body weight over 11 months of treatment. These results underscore Retatrutide's significant potential as a therapy that can meaningfully support weight loss in individuals with obesity."
%
Average body weight reduction after treatment.
x
Stronger appetite control than other options.
/10
Patients report improved health and energy.
days
First visible results appear within two weeks.
.webp)
Achieve Your Best Body with Retatrutide
Experience a breakthrough in weight management with Retatrutide, reducing hunger, improving vitality, and showing visible results in weeks.
Retatrutide vs Ozempic vs Zepbound: Head-to-Head Comparison
Semaglutide started the movement. Tirzepatide raised the bar. Now, Retatrutide is redefining what’s possible — delivering weight loss results no other treatment has achieved.
(Reta)
(Ozempic)
(Zepbound)
Register your interest in Retatrutide
Retatrutide is currently not available, but once it is approved, you’ll be the first to get notified. Sign up now and stay informed.
Simple one-time sign-up
Early access to availability updates
Exclusive status among the first users
Advantage over non-registered users
Retatrutide Research & Clinical Trial Insights
Evidence-based articles to support your journey toward sustainable health.
Frequently Asked Questions About Retatrutide
If you have any specific questions, feel free to reach out.
Retatrutide is a new experimental medication from the GLP-1/GIP/Glucagon agonist class, developed for the treatment of obesity and type 2 diabetes. It works by reducing appetite, slowing stomach emptying, and affecting hormones that regulate metabolism and body weight.
TRIUMPH-4 Phase 3 trial showed participants lost up to 28.7% of their body weight over 68 weeks at the 12mg dose. This translates to approximately 72 pounds for someone starting at 250 pounds. Results depend on dosage, diet, and exercise adherence.
Retatrutide is primarily being developed for obesity treatment, with TRIUMPH trials focusing on weight loss in people with and without diabetes. It also significantly improves blood sugar control, reducing HbA1c by approximately 2% in diabetic patients, making it beneficial for both conditions.
FDA approval is expected in late 2027 or early 2028, with commercial launch following 1-3 months later. Eli Lilly must complete all seven TRIUMPH Phase 3 trials and submit a New Drug Application before the FDA's 10-month review process begins. Realistic availability: Q1-Q2 2028.